Cyclo-oxygenase-2 inhibitors for chemoprevention of nonmelanoma skin cancer: Is there a role for these agents?

Liebman, Tracey N.; Stein, Jennifer A.; Polsky, David

doi:10.1016/j.jaad.2012.06.037

Cited by 11 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cyclooxygenase‐2 inhibitor, celecoxib, taken for 9 months can reduce the number of BCCs and SCCs over an 11‐month period, but does not appear to alter the number of AKs . Overall, it may have a role in high‐risk patients with multiple NMSCs, but it does not have evidence of a role for AK …”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017

Berker¹,

et al. 2017

View full text Add to dashboard Cite

Section: Treatmentmentioning

confidence: 99%

“…117 Overall, it may have a role in high-risk patients with multiple NMSCs, but it does not have evidence of a role for AK. 118…”

Section: Systemic Therapy (Strength Of Recommendation C Level Of Evimentioning

confidence: 99%

British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017

Berker¹,

et al. 2017

View full text Add to dashboard Cite

“…Selective inhibitors of COX-2 depress prostacyclin (PGI 2 ), an atheroprotective agent, but not COX-1-derived thromboxane A 2 (TXA 2 ), a proaggregatory and vasoconstrictor mediator, which might predispose patients to heart attack and stroke [4]. In 2004, Rofecoxib, (4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone), marketed as Vioxx was withdrawn from the market due to increased risk for cardiovascular thrombotic events in a long term-therapy [5].…”

Section: Introductionmentioning

confidence: 99%

Synthesis and biological evaluation of fluorinated 1,5-diarylpyrrole-3-alkoxyethyl ether derivatives as selective COX-2 inhibitors endowed with anti-inflammatory activity

Capua

Sticozzi

Brogi

et al. 2016

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

a b s t r a c tA series of substituted 1,5-diarylpyrrole-3-alkoxyethyl ethers were previously synthesized and the potential anti-inflammatory and antinociceptive activities of these compounds were evaluated in vivo. The compounds displayed a very good activity against both carrageenan-induced hyperalgesia and oedema in the rat paw test. Therefore, in a very preliminary test, compounds (8a,b) showed antiproliferative activity in the HaCaT (aneuploid immortal keratinocyte from adult human skin) cell models. On these basis, our research continued with the synthesis of fluorinated derivatives (8c,d, 9b-d, and 10b-d) with the aim of improving the pharmacokinetic profile of the previous active compounds. Substitution of a hydrogen atom by a fluorine atom may change the conformational preferences of the molecules due to stereoelectronic effects and also fluorine atom may be able to exert the metabolic obstruction reducing the "first-pass effect". Compound 10b exhibited a prominent in vivo anti-inflammatory and antinociceptive activities, in addition its antiproliferative power in an in vitro model of human skin cancer is herein described.

show abstract

“…Nonsteroidal anti‐inflammatory drugs (NSAIDs) are among the most commonly used drugs in pain management, representing a structurally diverse group of substances with anti‐inflammatory and analgesic properties . NSAIDs have been assigned a potential role in the chemoprevention of various malignancies including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC), which are collectively referred to as nonmelanoma skin cancer (NMSC) . Although the precise mechanism of anti‐tumorigenic activity is unknown, the inhibition of cyclooxygenase (COX) enzymes and the subsequent decrease in prostaglandin synthesis is thought to be of key importance.…”

mentioning

confidence: 99%

Nonsteroidal anti‐inflammatory drugs and the risk of nonmelanoma skin cancer

Reinau

Surber

Jick

et al. 2014

Intl Journal of Cancer

View full text Add to dashboard Cite

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been assigned a promising role in the chemoprevention of various malignancies. However, epidemiological data on the association between NSAID use and nonmelanoma skin cancer (NMSC) are limited. To explore whether patients regularly exposed to systemic NSAIDs are at a reduced risk of basal cell carcinoma (BCC) or squamous cell carcinoma (SCC), we conducted a population-based case-control analysis using the Clinical Practice Research Datalink, a United Kingdom primary care database. We identified 65,398 patients with incident BCC and 7,864 patients with incident SCC diagnosed between 1995 and 2013 and matched 1 and 4 NMSC-free controls to each BCC and SCC case, respectively, on age, sex, general practice, calendar time and years of history in the database. We compared prior NSAID exposure between cases and controls using multivariate conditional logistic regression analyses controlling for several potential confounders. Overall, we found no association between NSAID use and BCC, but when looking exclusively at users of single NSAID substances there was a suggestion of a reduced BCC risk in regular users of aspirin and ibuprofen (adjusted odds ratio

show abstract

Cyclo-oxygenase-2 inhibitors for chemoprevention of nonmelanoma skin cancer: Is there a role for these agents?

Cited by 11 publications

References 34 publications

British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017

British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017

Synthesis and biological evaluation of fluorinated 1,5-diarylpyrrole-3-alkoxyethyl ether derivatives as selective COX-2 inhibitors endowed with anti-inflammatory activity

Nonsteroidal anti‐inflammatory drugs and the risk of nonmelanoma skin cancer

Contact Info

Product

Resources

About